Food Supplement

Levigon

16.60 14.94

LEVIGON (Registered Patent) is a Food Supplement in a fast absorbed orange taste formulation containing Myo-Inositol, Liposomal Magnesium and Folic Acid.

Features

Food Supplement, 20 fast absorbed oral suspension stick pack. Registered Patent. Italian Parapharmaceutical Code: 923544011

LEVIGON (Registered Patent) contains Myo-Inositol, Liposomal Magnesium and Folic Acid in a fast absorbed formulation.

Magnesium has a role in the process of cell division and contributes to normal energy-yielding metabolism. Myo-Inositol is a natural compound, derived from glucose, that serves as precursor for intracellular second messengers involved in insulin signalling pathway. Folic Acid (Vitamin B9) is an hydrosoluble vitamin that has a role in the process f cell division and in normal functioning of the immune system. It also contributes to normal aminoacids synthesis and normal homocysteine metabolism.

The recommended dose is 1 or 2 stick packs per day. The product can be swallowed as is or diluted in water or other beverages.

Keep out of the reach of children under the age of 3. Do not exceed the recommended daily dose. Food supplements should not be intended or used as a substitute for a varied and balanced diet and a healthy lifestyle.

Gelfand JM, Yeung H., Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012 Jul;89:24-8. ;

Au SC, Goldminz AM, Loo DS, Dumont N, Levine D, Volf E, Michelon M, Wang A, Kim N, Yaniv S, Lizzul PF, Kerensky T, Lopez-Benitez JM, Natter M, Miller L, Pelajo CF, Davis T, Gottlieb AB., Association between pediatric psoriasis and the metabolic syndrome. J. Am Acad Dermatol. 2012 Jun;66(6):1012-3.;

Matarrelli B, Vitacolonna E, D’angelo M, Pavone G, Mattei PA, Liberati M, Celentano C., Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med. 2013 Mar 1. ;

Boehncke WH, Boehncke S, Buerger C., Beyond immunopathogenesis. Insulin resistance and “epidermal dysfunction”. Hautarzt. 2012 Mar;63(3):178-83. ;

Del Prete M, Mauriello MC, Faggiano A, Di Somma C, Monfrecola G, Fabbrocini G, Colao A., Insulin resistance and acne: a new risk factor for men? Endocrine. 2012 Dec;42(3):555-60.;

Mumcuoglu C, Ekmekci TR, Ucak S., The investigation of insulin resistance and metabolic syndrome in male patients with early-onset androgenetic alopecia. Eur J Dermatol. 2011 Jan-Feb;21(1):79-82 ;

Jucci A, Vignini M, Pelfini C, Criffŏ A, Fratino P., Psoriasis and insulin secretion. Preliminary results. Arch Dermatol Res. 1977 Jan 31;257(3):239-46. ;

Moro F, De Simone C, Morciano A, Tropea A, Sagnella F, Palla C, Scarinci E, Teti A, Caldarola G, D’Agostino M, Mancuso S, Lanzone A, Apa R., Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. Fertil Steril. 2012 Nov 16. ;

Piérard-franchimont C, Quatresooz P, Piérard GE, Scheen AJ., The psoriasis–metabolic syndrome comorbidity, a complex multigenic disease. Rev Med Liege. 2012 May-Jun;67(5-6):337-40 ;

Karadag AS, Ertugrul DT, Bilgili SG, Takci Z, Tutal E, Yilmaz H., Insulin resistance is increased in alopecia areata patients. Cutan Ocul Toxicol. 2013 Jun;32(2):102-6. ;

Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G., Can Alzheimer disease be a form of type 3 diabetes? Rejuvenation Res. 2012 Apr;15(2):217-21. ;

Condorelli RA, La Vignera S, Bellanca S, Vicari E, Calogero AE., Myoinositol: does it improve sperm mitochondrial function and sperm motility? Urology. 2012 Jun;79(6):1290-5. ;

Colone M, Marelli G, Unfer V, Bozzuto G, Molinari A, Stringaro A., Inositol activity in oligoasthenoteratospermia–an in vitro study. Eur Rev Med Pharmacol Sci. 2010 Oct;14(10):891-6. ;

Gelber D, Levine J, Belmaker RH., Effect of inositol on bulimia nervosa and binge eating. Int J Eat Disord. 2001 Apr;29(3):345-8. ;

Munekage E, Takezaki Y, Hanazaki K., Shortage and metabolic disturbance of magnesium in diabetic patients and significance of magnesium replacement therapy. Clin Calcium. 2012 Aug;22(8):1235-42. ;

Volpe SL., Magnesium, the metabolic syndrome, insulin resistance, and type 2 diabetes mellitus. Crit Rev Food Sci Nutr. 2008 Mar;48(3):293-300.

You may also like…